Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. Mangia A, et al. Among authors: mottola l. Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2. Gastroenterology. 2010. PMID: 20621700 Clinical Trial.
Treatment of non-genotype 1 hepatitis C virus patients.
Mangia A, Mottola L. Mangia A, et al. Among authors: mottola l. Curr Gastroenterol Rep. 2012 Feb;14(1):87-93. doi: 10.1007/s11894-011-0235-3. Curr Gastroenterol Rep. 2012. PMID: 22113745 Review.
What's new in HCV genotype 2 treatment.
Mangia A, Mottola L. Mangia A, et al. Among authors: mottola l. Liver Int. 2012 Feb;32 Suppl 1:135-40. doi: 10.1111/j.1478-3231.2011.02710.x. Liver Int. 2012. PMID: 22212584 Review.
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.
Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C. Mangia A, et al. Among authors: mottola l. J Hepatol. 2013 Aug;59(2):221-8. doi: 10.1016/j.jhep.2013.04.007. Epub 2013 Apr 12. J Hepatol. 2013. PMID: 23587473
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A. Mangia A, et al. Among authors: mottola l. Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8. Aliment Pharmacol Ther. 2010. PMID: 20222909 Free article.
Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
Mangia A, Bandiera F, Montalto G, Mottola L, Piazzolla V, Minerva N, Pellicelli A, Ricci GL, Cela M, Carretta V, Scotto G, Bacca D, Annicchiarico B, Romano M, Russello M, Barbarini G, Agostinacchio E, Andriulli A. Mangia A, et al. Among authors: mottola l. J Hepatol. 2010 Dec;53(6):1000-5. doi: 10.1016/j.jhep.2010.04.042. Epub 2010 Aug 4. J Hepatol. 2010. PMID: 20843575 Clinical Trial.
27 results